Background
Methods
Search strategy
Study selection
Quality assessment
Study quality | Criteria |
---|---|
High: small risk of bias | Prospective study design and the following: |
- Adequately described patients constituting a representative and clinically relevant sample | |
- Sample size ≥ 5000 | |
Moderate: moderate risk of bias | Prospective study design |
Low: high risk of selection and/or verification bias | Retrospective study design |
Selected or enriched samples |
Data collection and analysis
Results
Definition and frequency of hypoglycaemia
Definition
Frequency
High quality clinical studies on glycaemic control and CV outcome in diabetes
Study | Population | Design | Treatments | Outcome |
---|---|---|---|---|
1,441 T1D adolescents and adults (13–39 years old) with diabetes duration of 1–15 years | Effect of intensive vs. conventional treatment on micro- and macrovascular complications | Intensive treatment (multiple injections or pump) vs. standard therapy | ↓CVD by 54%, but only evident after long-term (>12-yr.) follow-up | |
5,102 newly diagnosed T2D adults | Randomized control trial of intensive therapy to reduce complications of T2D | Two intensive treatment arms (insulin/sulfonylurea or metformin) vs. conventional therapy | No significant differences in CV outcomes after trial, but 10-yr. follow-up revealed a modest reduction in CVD | |
10,251 T2D patients, 40–79 years of age with CV or 55–79 years of age with atherosclerosis or ≥ two risk factors | 3.5 yr. study; Randomized control trial of excellent HbA1c (<6%) vs. 7.0–7.9% | Combinations of all available treatments to achieve goal HbA1c | Study stopped early because of increased overall and CV mortality; primary CVD endpoint ↓10% (P=0.16); overall mortality ↑22% (P=0.04); CV mortality ↑35% (P=0.02) | |
ADVANCE [9] | 11,140 patients with T2D in 20 countries, ≥55 years of age and ≥30 years of age at diagnosis | 5 yr. study; tested if glucose lowering affected CV risk in T2D patients with at least one risk factor | Intensive glucose lowering (≤6.5%) vs. standard treatment | No difference in CV end point by treatment group; primary CVD endpoint ↓6% (P=0.37); overall mortality ↓7% (P=NS); CV mortality ↓12% (P=NS) |
1,791 patients with T2D on insulin or maximal-dose oral agents | 5.6 yr. study; determined effect of intensive glycaemic control on CV risk | Intensive treatment (<6.0%) vs. standard treatment | No difference in CV end point by treatment group; primary CVD endpoint ↓13% (P=0.12); overall mortality ↑6.5% (P=NS); CV mortality ↑25% (P=NS) | |
ORIGIN [47] | 12,537 patients with IFG, IGT or T2D on insulin glargine or standard of care | 6.2 yr study; determined effect of early insulin treatment on CV events | Insulin glargine vs. standard of care | No differences in the rate of CV events (P=0.63/0.27) |
Mechanistic studies linking hypoglycaemia and CV risk in diabetes
Risk factor | Hypoglycaemic-associated effect contributing to risk factor | Reference(s) |
---|---|---|
Thrombotic tendency | ↑ platelet-monocyte aggregation | [14] |
↑ soluble P-selectin levels | ||
↑ plasminogen activator inhibitor-1 | [48] | |
↓ partial thromboplastin time | [49] | |
↑ fibrinogen and factor VIII | [49] | |
Abnormal cardiac repolarization | ↑ catecholamines (hypokalaemia) | |
Inflammation | ↑ QT interval and QT dispersal | |
↑ CD40 expression on monocytes | [14] | |
↑ soluble CD40L in serum | [14] | |
↑ IL-6, IL-8, TNF-α, and IL-1β | ||
↑ ICAM, VCAM, E-selectin, and VEGF | ||
Atherosclerosis | ↑ inflammation | see above |
↑ endothelial dysfunction | ||
↑ oxidative stress | [57] | |
↑ Aldosterone | [61] | |
↑ ICAM, VCAM, and E-selectin | [48] |